Biosimilars: US Payer Insights

Biosimilars: US Payer Insights

Why might 2023 be a good year for the US biosimilars market?

Delayed regulation, stakeholder anxieties, disappointing discounts and aggressive originator defence strategies have all played their part in the sluggish US biosimilar sector development. But is that about to change? Will the launch of biosimilar adalimumab re-invigorate the sector? How is the Inflation Reduction Act impacting biosimilars? Why is it critical for developers to educate stakeholders about their biosimilar brands. Turn to this report for insights into the developments and challenges that are shaping the US biosimilars sector.

Products

Enbrel, Humira, Remicade, Rituxan/MabThera, Inflectra, Herceptin, Ontruzant, Avastin, Lantus, Idacio, Vegzelma, Stimufend, Cimerli, Fylnetra, Neulasta, Alymsys, Releuko, Neupogen, Yusimry, Rezvoglar, Byooviz, Lucentis, Semglee, Riabni, Hulio, Nyvepria, Avsola, Abrilada, Ziextenzo, Hadlima, Ruxience, Zirabev, Kanjinti, Eticovo, Trazimera, Herzuma, Truxima, Udenyca, Hyrimoz, Nivestym, Fulphila, Retacrit, Epogen, Ixifi, Ogivri, Mvasi, Cyltezo, Renflexis, Amjevita, Erelzi, Zarxio

Companies

AbbVie, Amgen, Novartis, Pfizer, Boehringer Ingelheim, Samsung Bioepis, Coherus, Organon, Viatris, Fresenius Kabi